RANI — Rani Therapeutics Holdings, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1856725 ·
Last close
$0.76
Market Cap
$87.61M
52W High
$3.87
52W Low
$0.44
ADV30
664,690
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 1,708,000 | — | -8,828,000 | -7,391,000 | 60,843,000 | 4,868,000 | 12,858,000 |
| Mar 2026 | 1,708,000 | — | -8,339,000 | -7,033,000 | 51,879,000 | 9,644,000 | 16,336,000 |
| Dec 2025 | 1,461,000 | — | -8,535,000 | -10,305,000 | 58,621,000 | 18,618,000 | 17,109,000 |
| Sep 2025 | 0 | — | -7,257,000 | -5,412,000 | 10,139,000 | 4,144,000 | 22,112,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-17,062,000
Investing CF
$-27,709,000
Financing CF
$44,004,000
CapEx
$-134,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.41
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-139,613,000
Inventory
—
Receivables
$2,042,000
ST Investments
$33,759,000
EBIT TTM
$-34,190,000
Pretax Income TTM
$-36,227,000
Interest Exp TTM
$2,037,000
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$4,877,000
EBITDA
$-32,237,000
Free Cash Flow
$-8,874,375
Enterprise Value
$56,166,072
Total Cash
$53,391,000
Total Debt
$3,549,000
Shares Out
115,424,960
Trailing EPS
$-0.13
Book Value
$0.35
ROE
-172.1%
ROA
-53.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 1,633,000 | -38,310,000 | -29,673,000 | 58,621,000 | 17,109,000 | 33,010,000 | -18,714,000 |
| Dec 2024 | 1,028,000 | -49,600,000 | -30,018,000 | 36,634,000 | 33,141,000 | 1,992,000 | -35,496,000 |
| Dec 2023 | 0 | -66,099,000 | -33,970,000 | 57,916,000 | 32,473,000 | 12,866,000 | -51,236,000 |
| Dec 2022 | 0 | -63,451,000 | -30,588,000 | 108,027,000 | 34,023,000 | 36,855,000 | -46,515,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.19
Max Pain — expiry 2026-10-16
max pain strike: $1.00 · spot: $0.76 · call oi: 1,968 · put oi: 133Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| RLYB | Rallybio Corp | $88.26M | $16.62 | — |
| RVRC | Revium Rx. | $86.84M | $1.43 | — |
| ONCY | ONCOLYTICS BIOTECH INC | $86.71M | $0.68 | — |
| ACRV | Acrivon Therapeutics, Inc. | $89.99M | $2.10 | — |
| RACC | Research Alliance Corp III | $84.90M | $10.92 | — |
News headlines (Yahoo Finance, 1h cache)
Rani Therapeutics to Participate in Upcoming September Conferences
2026-09-08 12:00 · Yahoo
Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Update
2026-08-13 20:05 · Yahoo
Rani Therapeutics Appoints Michelle Gilson to Board of Directors
2026-08-04 12:00 · Yahoo
Rani Therapeutics Holdings, Inc. Announces Pricing of $20.0 Million Registered Direct Offering of Class A Common Stock Priced At-The-Market Under Nasdaq Rules
2026-05-26 12:00 · Yahoo
Rani Therapeutics Expands Oral Biologics Push With Obesity, Immunology Pipeline
2026-08-16 20:01 · Yahoo
Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-07-20 20:05 · Yahoo
Rani Therapeutics Appoints Nicholas Maestas as Chief Financial Officer
2026-06-29 12:00 · Yahoo
Rani Therapeutics to Participate in the H.C. Wainwright Annual BioConnect Investor Conference
2026-05-12 20:05 · Yahoo
Rani Therapeutics Appoints Dr. Sara Kenkare-Mitra as Strategic Advisor to Advance Platform and Clinical Strategy
2026-04-09 11:00 · Yahoo
3 Small Cap Biotech Stocks Trading At A Discount With Late Stage Clinical Catalysts
2026-08-28 04:44 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.